Curt Robbins on terpenes, Indica/Sativa & what the next big cannabinoid is | The Cannabis Review
Description
In this episode, Patrick chats to one Curt Robbins, considered to be one of the god fathers of the cannabis industry. Curt Robbins is a technical writer, instructional designer, and lecturer who has been developing science-based educational and training content for Fortune 200 enterprise companies for more than 30 years. His clients have included Federal Express, Microsoft, Sun Microsystems, Northrop Grumman, National City Bank, Strainprint Technologies Ltd., the J.M. Smucker Company, and USAA. He is Director of Courseware Development at Higher Learning LV™ in Las Vegas, Nevada.
Robbins began writing about the biochemistry and science of the various wellness molecules produced by plants such as hemp in 2003. He has since developed more than 600 educational articles about hemp and its myriad health components—including terpenes, cannabinoids, and the human endocannabinoid system. In 2019, Robbins developed a 50-page white paper regarding the hemp cannabinoid cannabigerol (CBG) that explored a fourth potential species of the unique plant genus.
4:00 - The Oasis Intelligence Survey on prospective and current consumers 6:00 - What are terpenes and the entourage effect? 7:00 - THCVa THCV1, CBG 8:00 - Terpenes in cannabis 9:00 - Flavinoids & cannaflavins 10:00 - THC 13:00 - Misunderstanding between indica and sativa 14:00 - What is the Endocannabinoid systems (ECS) 18:00 - Cannabis and cancer - anti-inflammatory 19:00 - CB1 receptors and CB2 receptors 24:00 - Cannabis is a vegetable not a a herb 27:00 - Patient efficacy 30:00 - Curt's top cannabis brands 33:00 - What is the next big cannabinoid?
#IMNCannabisReview #thecannabisreview #medicalcannabis #imn #regennabis #curtrobbins #terpenes #cannabinoid #cannabis #europeancannabis #cannabismedia #cannabiscontent #irishmedianetwork #cbd
United States
